KZIA
HEALTHCAREKazia Therapeutics Ltd
$13.84+0.39 (+2.90%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KZIA Today?
No stock-specific AI insight has been generated for KZIA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.19$17.40
$13.84
Fundamentals
Market Cap$153M
P/E Ratio—
EPS$-7.66
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume172K
Avg Volume (10D)—
Shares Outstanding11.4M
KZIA News
20 articles- How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and PlatformYahoo Finance·Apr 28, 2026
- Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology PlatformYahoo Finance·Apr 15, 2026
- Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development PlatformBenzinga·Apr 13, 2026
- Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)Yahoo Finance·Jan 30, 2026
- Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast CancerYahoo Finance·Jan 27, 2026
- Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-EndYahoo Finance·Jan 8, 2026
- US Equity Futures Mixed Pre-Bell Monday Despite Oil Sector SurgeYahoo Finance·Jan 5, 2026
- Kazia Therapeutics Regains Full Nasdaq Listing ComplianceYahoo Finance·Dec 22, 2025
- Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+Yahoo Finance·Dec 10, 2025
- Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity SecuritiesYahoo Finance·Dec 2, 2025
- Traders Await Nvidia Earnings, Fed Minutes, Driving Narrow Premarket Gains for US Equity FuturesYahoo Finance·Nov 19, 2025
- Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory StrategyYahoo Finance·Nov 18, 2025
- Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunnerYahoo Finance·Oct 27, 2025
- Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader ProgramYahoo Finance·Oct 7, 2025
- Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy RegimenYahoo Finance·Oct 2, 2025
- Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMGYahoo Finance·Oct 1, 2025
- Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib MonotherapyYahoo Finance·Sep 11, 2025
- Kazia Therapeutics Announces $2 Million Private Placement at Premium to MarketYahoo Finance·Aug 1, 2025
- Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock JumpsYahoo Finance·Jul 9, 2025
- Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialYahoo Finance·Jul 9, 2025
All 20 articles loaded
Price Data
Open$13.45
Previous Close$13.45
Day High$13.46
Day Low$12.78
52 Week High$17.40
52 Week Low$3.19
52-Week Range
$3.19$17.40
$13.84
Fundamentals
Market Cap$153M
P/E Ratio—
EPS$-7.66
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin—
Debt / Equity—
Trading
Volume172K
Avg Volume (10D)—
Shares Outstanding11.4M
About Kazia Therapeutics Ltd
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—